BioSpecifics Technologies Reports Positive Data from Phase 2b Study of CCH

BioSpecifics Technologies (NASDAQ:BSTC) today reports positive results from a Phase 2b study of CCH, which treats cellulite or edematous fibrosclerotic panniculopathy.
According to the press release:

Trial subjects receiving CCH showed statistically significant levels of improvement in the appearance of cellulite with treatment, as measured by the trial’s primary endpoint (p<0.001), compared to those subjects receiving placebo. CCH was well-tolerated in the actively treated subjects with most adverse events being mild to moderate in severity, and primarily limited to the local injection area.

President Thomas L. Wegman said the following:

“Like in the prior Phase 2a study, these positive results are very encouraging, particularly because both patients and physicians saw a statistically significant improvement in the appearance of cellulite after CCH treatment.”

Read the full press release here.